REX1BD

Across TCGA pan-cancer cohorts, REX1BD Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated REX1BD data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher REX1BD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated REX1BD expression acts as an unfavorable survival marker.

STAD, LIHC, and ESCA are the cancer types where REX1BD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.250	0.729	.028	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

REX1BD–STAD (OS)

Open the STAD breakdown →